Management of priapism: An update for clinicians

Therapeutic Advances in Urology

Volumn 6, Issue 6, 2014, Pages 230-244

  Levey, Helen R ^a   Segal, Robert L ^b   Bivalacqua, Trinity J ^c  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

guidelines; ischemic; non ischemic; priapism; recurrent; stuttering

Indexed keywords

ADENOSINE; ADRENALIN; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANDROGEN RECEPTOR ANTAGONIST; BACLOFEN; DIGOXIN; ENKEPHALINASE INHIBITOR; EPHEDRINE; GABAPENTIN; GONADORELIN AGONIST; KETOCONAZOLE; METARAMINOL; NORADRENALIN; OPIORPHIN DERIVATIVE; PHENYLEPHRINE; PHOSPHODIESTERASE V INHIBITOR; STEROID 5ALPHA REDUCTASE INHIBITOR; TERBUTALINE; UNCLASSIFIED DRUG;

CORPUS CAVERNOSUM; DRUG MECHANISM; HUMAN; ISCHEMIC PRIAPISM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PENIS PROSTHESIS; PRIAPISM; PRIORITY JOURNAL; RADIODIAGNOSIS; REVIEW; SHUNTING; STUTTERING PRIAPISM;

EID: 84921763581     PISSN: 17562872     EISSN: 17562880     Source Type: Journal    
DOI: 10.1177/1756287214542096     Document Type: Review

References (87)

1. Abern M. Levine L. (2009) Ketoconazole and prednisone to prevent recurrent ischemic priapism. J Urol 182: 1401–1406.
2. Bennett N. Mulhall J. (2008) Sickle cell disease status and outcomes of African-American men presenting with priapism. J Sex Med 5: 1244–1250.
3. Berger R. Billups K. Brock G. Broderick GA. Dhabuwala CB. Goldstein I. (2001) Report of the American Foundation for Urologic Disease (AFUD) Thought Leader Panel for evaluation and treatment of priapism. Int J Impot Res 13(Suppl. 5): S39–43.
4. Bertram R Carson C. 3rd Webster G. (1985) Implantation of penile prostheses in patients impotent after priapism. Urology 26: 325–327.
5. Bivalacqua T. Burnett A. (2006) Priapism: new concepts in the pathophysiology and new treatment strategies. Curr Urol Rep 7: 497–502.
6. Bivalacqua T. Musicki B. Hsu L. Gladwin M. Burnett A. Champion H. (2009) Establishment of a transgenic sickle-cell mouse model to study the pathophysiology of priapism. J Sex Med 6: 2494–2504.
7. Bivalacqua T. Musicki B. Kutlu O. Burnett A. (2012) New insights into the pathophysiology of sickle cell disease-associated priapism. J Sex Med 9: 79–87.
8. Brant W. Garcia M. Bella A. Chi T. Lue T. (2009) T-shaped shunt and intracavernous tunneling for prolonged ischemic priapism. J Urol 181: 1699–1705.
9. Broderick G. Harkaway R. (1994) Pharmacologic erection: time-dependent changes in the corporal environment. Int J Impot Res 6: 9–16.
10. Broderick G. Kadioglu A. Bivalacqua T. Ghanem H. Nehra A. Shamloul R. (2010) Priapism: pathogenesis, epidemiology, and management. J Sex Med 7: 476–500.
11. Burnett A. (2003) Pathophysiology of priapism: dysregulatory erection physiology thesis. J Urol 170: 26–34.
12. Burnett A. Bivalacqua T. (2007) Priapism: current principles and practice. Urol Clin North Am 34: 631–642, viii.
13. Burnett A. Bivalacqua T. (2008) Glucose-6-phosphate dehydrogenase deficiency: an etiology for idiopathic priapism? J Sex Med 5: 237–240.
14. Burnett A. Bivalacqua T. Champion H. Musicki B. (2006a) Feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism. J Sex Med 3: 1077–1084.
15. Burnett A. Bivalacqua T. Champion H. Musicki B. (2006b) Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism. Urology 67: 1043–1048.
16. Burnett A. Kan-Dobrosky N. Miller M. (2013) Testosterone replacement with 1% testosterone gel and priapism: no definite risk relationship. J Sex Med 10: 1151–1161.
17. Burnett A. Pierorazio P. (2009) Corporal ‘snake– maneuver: corporoglanular shunt surgical modification for ischemic priapism. J Sex Med 6: 1171–1176.
18. Burnett A. Sharlip I. (2013) Standard operating procedures for priapism. J Sex Med 10: 180–194.
19. Champion H. Bivalacqua T. Takimoto E. Kass D. Burnett A. (2005) Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism. Proc Natl Acad Sci U S A 102: 1661–1666.
20. Chinegwundoh F. Anie K. (2004) Treatments for priapism in boys and men with sickle cell disease. Cochrane Database Syst Rev (4): CD004198.
21. Chung S. Stein R. Cannon T. Nelson J. (2003) Novel technique in the management of low flow priapism. J Urol 170: 1952.
22. Dai Y. Zhang Y. Phatarpekar P. Mi T. Zhang H. Blackburn MR. (2009) Adenosine signaling, priapism and novel therapies. J Sex Med 6(Suppl. 3): 292–301.
23. D–Aleo G. Rifici C. Kofler M. Saltuari L. Bramanti P. (2009) Favorable response to intrathecal, but not oral, baclofen of priapism in a patient with spinal cord injury. Spine (Phila Pa 1976) 34: E127–E129.
24. Daoud A. Bataineh H. Otoom S. Abdul-Zahra E. (2004) The effect of vigabatrin, lamotrigine and gabapentin on the fertility, weights, sex hormones and biochemical profiles of male rats. Neuro Endocrinol Lett 25: 178–183.
25. Davila H. Parker J. Webster J. Lockhart J. Carrion R. (2008) Subarachnoid hemorrhage as complication of phenylephrine injection for the treatment of ischemic priapism in a sickle cell disease patient. J Sex Med 5: 1025–1028.
26. DeCastro B. Costabile R. McMann L. Peterson A. (2008) Oral ketoconazole for prevention of postoperative penile erection: a placebo controlled, randomized, double-blind trial. J Urol 179: 1930–1932.
27. Denys P. Mane M. Azouvi P. Chartier-Kastler E. Thiebaut J. Bussel B. (1998) Side effects of chronic intrathecal baclofen on erection and ejaculation in patients with spinal cord lesions. Arch Phys Med Rehabil 79: 494–496.
28. Dong Q. Deng S. Wang R. Yuan J. (2011) In vitro and in vivo animal models in priapism research. J Sex Med 8: 347–359.
29. Douglas L. Fletcher H. Serjeant G. (1990) Penile prostheses in the management of impotence in sickle cell disease. Br J Urol 65: 533–535.
30. Earle C. Stuckey B. Ching H. Wisniewski Z. (2003) The incidence and management of priapism in Western Australia: a 16 year audit. Int J Impot Res 15: 272–276.
31. Eland I. van der Lei J. Stricker B. Sturkenboom M. (2001) Incidence of priapism in the general population. Urology 57: 970–972.
32. Emond A. Holman R. Hayes R. Serjeant G. (1980) Priapism and impotence in homozygous sickle cell disease. Arch Intern Med 140: 1434–1437.
33. Evans K. Peterson A. Ruiz H. Costabile R. (2004) Use of oral ketoconazole to prevent postoperative erections following penile surgery. Int J Impot Res 16: 346–349.
34. Feldstein V. (1993) Posttraumatic ‘high-flow– priapism evaluation with color flow Doppler sonography. J Ultrasound Med 12: 589–593.
35. Filippi S. Mancini M. Amerini S. Bartolini M. Natali A. Mancina R. (2000) Functional adenosine receptors in human corpora cavernosa. Int J Androl 23: 210–217.
36. Garcia M. Shindel A. Lue T. (2008) T-shunt with or without tunnelling for prolonged ischaemic priapism. BJU Int 102: 1754–1764.
37. Govier F. Jonsson E. Kramer-Levien D. (1994) Oral terbutaline for the treatment of priapism. J Urol 151: 878–879.
38. Gupta S. Moreland R. Munarriz R. Daley J. Goldstein I. Saenz de Tejada I. (1995) Possible role of Na(+)-K(+)-ATPase in the regulation of human corpus cavernosum smooth muscle contractility by nitric oxide. Br J Pharmacol 116: 2201–2206.
39. Gupta S. Salimpour P. Saenz de Tejada I. Daley J. Gholami S. Daller M. (1998) A possible mechanism for alteration of human erectile function by digoxin: inhibition of corpus cavernosum sodium/potassium adenosine triphosphatase activity. J Urol 159: 1529–1536.
40. Hannan J. Albersen M. Kutlu O. Gratzke C. Stief CG. Burnett AL. (2013) Inhibition of Rho-kinase improves erectile function, increases nitric oxide signaling and decreases penile apoptosis in a rat model of cavernous nerve injury. J Urol 189: 1155–1161.
41. Kandel G. Bender L. Grove J. (1968) Pulmonary embolism: a complication of corpus-saphenous shunt for priapism. J Urol 99: 196–197.
42. Kanika N. Tar M. Tong Y. Kuppam D. Melman A. Davies K. (2009) The mechanism of opiorphin-induced experimental priapism in rats involves activation of the polyamine synthetic pathway. Am J Physiol Cell Physiol 297: C916–C927.
43. Kato G. Wang Z. Machado R. Blackwelder W. Taylor J. Hazen S. (2009) Endogenous nitric oxide synthase inhibitors in sickle cell disease: abnormal levels and correlations with pulmonary hypertension, desaturation, haemolysis, organ dysfunction and death. Br J Haematol 145: 506–513.
44. Kim N. Kim J. Hypolite J. Garcia-Diaz JF. Broderick GA. Tornheim K. (1996) Altered contractility of rabbit penile corpus cavernosum smooth muscle by hypoxia. J Urol 155(2): 772–778.
45. Kulmala R. Lehtonen T. Tammela T. (1995) Priapism, its incidence and seasonal distribution in Finland. Scand J Urol Nephrol 29: 93–96.
46. Levey HR. Kutlu O. Bivalacqua T. (2012) Medical management of ischemic stuttering priapism: a contemporary review of the literature. Asian J Androl 14: 156–163.
47. Liu S. Mogavero L. Levin R. (1999) Correlation of calcium-activated ATPase activity, lipid peroxidation, and the contractile response of rabbit corporal smooth muscle treated with in vitro ischemia. Gen Pharmacol 32: 345–349.
48. Lowe F. Jarow J. (1993) Placebo-controlled study of oral terbutaline and pseudoephedrine in management of prostaglandin E1-induced prolonged erections. Urology 42: 51–53; discussion 53–54.
49. Lue T. Hellstrom W. McAninch J. Tanagho E. (1986) Priapism: a refined approach to diagnosis and treatment. J Urol 136: 104–108.
50. Mantadakis E. Cavender J. Rogers Z. Ewalt D. Buchanan G. (1999) Prevalence of priapism in children and adolescents with sickle cell anemia. J Pediatr Hematol Oncol 21: 518–522.
51. Mantadakis E. Ewalt D. Cavender J. Rogers Z. Buchanan G. (2000) Outpatient penile aspiration and epinephrine irrigation for young patients with sickle cell anemia and prolonged priapism. Blood 95: 78–82.
52. Mi T. Abbasi S. Zhang H. Uray K. Chunn JL. Xia LW. (2008) Excess adenosine in murine penile erectile tissues contributes to priapism via A2B adenosine receptor signaling. J Clin Invest 118: 1491–1501.
53. Monga M. Broderick G. Hellstrom W. (1996) Priapism in sickle cell disease: the case for early implantation of the penile prosthesis. Eur Urol 30: 54–59.
54. Montague D. Angermeier K. (2006) Corporeal excavation: new technique for penile prosthesis implantation in men with severe corporeal fibrosis. Urology 67: 1072–1075.
55. Montague D. Jarow J. Broderick G. Dmochowski RR. Heaton JP. Lue TF. (2003) American Urological Association guideline on the management of priapism. J Urol 170: 1318–1324.
56. Montorsi F. Adaikan G. Becher E. Giuliano F. Khoury S. Lue TF. (2010) Summary of the recommendations on sexual dysfunctions in men. J Sex Med 7: 3572–3588.
57. Moon D. Lee D. Kim J. (1999) Altered contractile response of penis under hypoxia with metabolic acidosis. Int J Impot Res 11: 265–271.
58. Morrison B. Reid M. Madden W. Burnett A. (2013) Testosterone replacement therapy does not promote priapism in hypogonadal men with sickle cell disease: 12-month safety report. Andrology 1: 576–582.
59. Muneer A. Cellek S. Ralph D. Minhas S. (2008a) The investigation of putative agents, using an in vitro model, to prevent cavernosal smooth muscle dysfunction during low-flow priapism. BJU Int 102: 988–992.
60. Muneer A. Minhas S. Arya M. Ralph D. (2008b) Stuttering priapism – a review of the therapeutic options. Int J Clin Pract 62: 1265–1270.
61. Mwamukonda K. Chi T. Shindel A. Lue T. (2010) Androgen blockade for the treatment of high-flow priapism. J Sex Med 7: 2532–2537.
62. Nixon R. O–Connor J. Milam D. (2003) Efficacy of shunt surgery for refractory low flow priapism: a report on the incidence of failed detumescence and erectile dysfunction. J Urol 170: 883–886.
63. Nolan V. Wyszynski D. Farrer L. Steinberg M. (2005) Hemolysis-associated priapism in sickle cell disease. Blood 106: 3264–3267.
64. Perimenis P. Athanasopoulos A. Papathanasopoulos P. Barbalias G. (2004) Gabapentin in the management of the recurrent, refractory, idiopathic priapism. Int J Impot Res 16: 84–85.
65. Pierorazio P. Bivalacqua T. Burnett A. (2011) Daily phosphodiesterase type 5 inhibitor therapy as rescue for recurrent ischemic priapism after failed androgen ablation. J Androl 32: 371–374.
66. Pohl J. Pott B. Kleinhans G. (1986) Priapism: a three-phase concept of management according to aetiology and prognosis. Br J Urol 58: 113–118.
67. Pryor J. Hehir M. (1982) The management of priapism. Br J Urol 54: 751–754.
68. Ralph D. Borley N. Allen C. Kirkham A. Freeman A. Minhas S. (2010) The use of high-resolution magnetic resonance imaging in the management of patients presenting with priapism. BJU Int 106: 1714–1718.
69. Ralph D. Garaffa G. Muneer A. Freeman A. Rees R. Christopher AN. (2009) The immediate insertion of a penile prosthesis for acute ischaemic priapism. Eur Urol 56: 1033–1038.
70. Rees R. Kalsi J. Minhas S. Peters J. Kell P. Ralph D. (2002) The management of low-flow priapism with the immediate insertion of a penile prosthesis. BJU Int 90: 893–897.
71. Roghmann F. Becker A. Sammon J. Ouerghi M. Sun M. Sukumar S. (2013) Incidence of priapism at emergency departments in the United States. J Urol 190: 1275–1280.
72. Rourke K. Fischler A. Jordan G. (2002) Treatment of recurrent idiopathic priapism with oral baclofen. J Urol 168: 2552; discussion 2552–2553.
73. Saenz de Tejada I. Kim N. Daley J. Royai R. Hypolite J. Broderick GA. (1997) Acidosis impairs rabbit trabecular smooth muscle contractility. J Urol 157: 722–726.
74. Segal R. Readal N. Pierorazio P. Burnett A. Bivalacqua T. (2013) Corporal Burnett ‘Snake– surgical maneuver for the treatment of ischemic priapism: long-term followup. J Urol 189: 1025–1029.
75. Shalev M. Staerman F. Allain H. Lobel B. Saiag B. (1999) Stimulation of P2y purinoceptors induces, via nitric oxide production, endothelium-dependent relaxation of human isolated corpus cavernosum. J Urol 161: 955–959.
76. Sharifzadeh M. Zarrindast M. Samini M. (1995) Effects of adenosine analogues on apomorphine-induced penile erection in rats. Gen Pharmacol 26: 1785–1790.
77. Shiraishi K. Matsuyama H. (2013) Salvage management of prolonged ischemic priapism: Al-Ghorab shunt plus cavernous tunneling with blunt cavernosotomy. J Sex Med 10: 599–602.
78. Soni B. Vaidyanathan S. Krishnan K. (1994) Management of pharmacologically induced prolonged penile erection with oral terbutaline in traumatic paraplegics. Paraplegia 32: 670–674.
79. Tabibi A. Abdi H. Mahmoudnejad N. (2010) Erectile function and dysfunction following low flow priapism: a comparison of distal and proximal shunts. Urol J 7: 174–177.
80. Tausch T. Evans L. Morey A. (2007) Immediate insertion of a semirigid penile prosthesis for refractory ischemic priapism. Mil Med 172: 1211–1212.
81. Tzortzis V. Mitrakas L. Gravas S. Mamoulakis C. Meissner A. Kyriakou D. (2009) Oral phosphodiesterase type 5 inhibitors alleviate recurrent priapism complicating thalassemia intermedia: a case report. J Sex Med 6: 2068–2071.
82. Upadhyay J. Shekarriz B. Dhabuwala C. (1998) Penile implant for intractable priapism associated with sickle cell disease. Urology 51: 638–639.
83. Van der Horst C. Stuebinger H. Seif C. Melchior D. Martinez-Portillo F. Juenemann K. (2003) Priapism – etiology, pathophysiology and management. Int Braz J Urol 29: 391–400.
84. Wen J. Jiang X. Dai Y. Zhang Y. Tang Y. Sun H. (2010) Increased adenosine contributes to penile fibrosis, a dangerous feature of priapism, via A2B adenosine receptor signaling. FASEB J 24: 740–749.
85. Winter C. McDowell G. (1988) Experience with 105 patients with priapism: update review of all aspects. J Urol 140: 980–983.
86. Yuan J. Desouza R. Westney O. Wang R. (2008) Insights of priapism mechanism and rationale treatment for recurrent priapism. Asian J Androl 10: 88–101.
87. Zheng D. Yao H. Zhang K. Xu MX. Chen Q. Chen YB. (2013) Unsatisfactory outcomes of prolonged ischemic priapism without early surgical shunts: our clinical experience and a review of the literature. Asian J Androl 15: 75–78.